Dermatology Roundup: Atopic Dermatitis Treatments, Biosimilar Approval, and More

Nemolizumab for Atopic Dermatitis Shows Positive Results in Phase 3 Trials

Dermatology Roundup: Atopic Dermatitis Treatments, Biosimilar Approval, and More / Ltyuan - stock.adobe.com

Positive results from 2 phase 3 clinical trials evaluating the efficacy and safety of nemolizumab in adolescent and adult patients with moderate to severe atopic dermatitis were announced. Results from the ARCADIA 1 and ARCADIA 2 trials showed the therapy met the co-primary endpoints of an Investigator's Global Assessment (IGA) success score of 0 or 1 with a 2 or more point improvement from baseline at 16 weeks and at least 75% improvement in Eczema Area and Severity Index score.

Long-Term Oral Corticosteroid Use for AD Associated with Increased Risk of Adverse Events

Patients with exacerbations of atopic dermatitis (AD) who take oral corticosteroids to treat their condition for over 90 days may be at an increased risk of experiencing adverse events, according to research published in JAMA Network Open. The authors said the study findings support the continual monitoring for adverse events when patients are taking oral corticosteroids.

Chronic Hand Eczema Treatment Shows Positive Results in Phase 3 Trials

Positive results from 2 phase 3 trials evaluating the safety and efficacy of twice-daily delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) were announced. Results from the DELTA 1 and DELTA 2 trials showed twice-daily delgocitinib cream met its primary endpoint of an Investigator’s Global Assessment for chronic hand eczema treatment success (IGA-CHE TS) score of 0 or 1.

Mediterranean Diet, Omega-3 Supplements May Reduce Acne Severity

Following a Mediterranean diet and taking omega-3 supplements may help reduce acne severity in patients with mild to moderate cases, according to new research published in the Journal of Cosmetic Dermatology. The study also showed that increased omega-3 levels led to improved clinical appearance and quality of life.

Stigmatization Plays Key Role in the Mental Health of Children with Skin Disease

While chronic skin disorders can be difficult for children to manage, the stigmatization of their diseases can trigger poor mental health and quality of life (QOL) outcomes. Researchers found a significant number of cases where mental health and QOL was exacerbated in children with skin disorders because of bullying and other negative sentiments toward the visibility of their ailments, according to a study published in JAMA Dermatology.

CGRP Monoclonal Antibody May Reduce Flushing, Chronic Erythema in Rosacea

Calcitonin gene-related peptide (CGRP)-receptor monoclonal antibody erenumab may be effective in reducing flushing and chronic erythema associated with rosacea, according to research results published in JAMA Dermatology. CGRP has been previously associated with pathogenesis of rosacea due to its triggering of vasodilation and inflammation.

Third Ustekinumab Biosimilar Gains FDA Approval

The FDA approved ustekinumab (Stelara) biosimilar ustekinumab-ttwe (Pyzchiva) for all of the same indications as the reference medication. The drug has also been granted a provisional determination for interchangeability designation. Ustekinumab-ttwe is available for subcutaneous injection in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes, and for intravenous infusion in a 130 mg/26 mL (5 mg/mL) single-dose vial.

FDA Approves Roflumilast Cream 0.15% for Atopic Dermatitis in Pediatric, Adult Patients

The FDA approved the supplemental new drug application (sNDA) for roflumilast cream, 0.15% (Zoryve) for the treatment of mild to moderate atopic dermatitis (AD) in adult and pediatric patients aged 6 years and older. The cream provides rapid disease clearance and significant reduction in itch to patients and has been specifically formulated for long-term disease control.

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.